Curated News
By: NewsRamp Editorial Staff
October 20, 2025
Kairos Pharma's Prostate Cancer Therapy Shows 86% Clinical Benefit
TLDR
- Kairos Pharma's ENV-105 shows 86% clinical benefit in prostate cancer trials, positioning the company as a leader in overcoming cancer treatment resistance.
- ENV-105 targets CD105 protein to reverse drug resistance, combined with apalutamide in Phase 2 trials showing sustained progression-free survival in prostate cancer patients.
- This therapy offers new hope for prostate cancer patients by potentially restoring treatment effectiveness and extending progression-free survival beyond current standards.
- Kairos Pharma's innovative antibody targets a resistance protein, showing remarkable 86% clinical benefit in advanced prostate cancer patients during ongoing trials.
Impact - Why it Matters
This development represents a potential breakthrough in treating metastatic castration-resistant prostate cancer, one of the most challenging forms of prostate cancer that has stopped responding to standard hormone therapies. For patients facing limited treatment options and poor prognoses, ENV-105's ability to restore hormone responsiveness and demonstrate high clinical benefit rates could significantly extend survival and improve quality of life. The therapy's mechanism of targeting CD105 to reverse drug resistance addresses a fundamental problem in cancer treatment that affects multiple cancer types, suggesting broader applications beyond prostate cancer. Successful development of this approach could transform treatment paradigms for resistant cancers and provide new hope for patients who have exhausted conventional options.
Summary
Kairos Pharma Ltd., a clinical-stage biopharmaceutical company trading on the NYSE American under the ticker KAPA, has announced promising interim results from its ongoing Phase 2 clinical trial for ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer. The data, presented at the prestigious European Society for Medical Oncology meeting in Berlin, revealed that 86% of patients treated with the combination of ENV-105 and apalutamide demonstrated clinical benefit, with all responders remaining progression-free for at least four months and half continuing beyond one year. The study, conducted in collaboration with leading institutions including Cedars-Sinai, also showed that seven out of nine evaluable patients experienced significant PSA reductions, indicating the therapy's potential to restore hormone responsiveness in this challenging patient population.
The company's innovative approach focuses on overcoming one of oncology's most persistent challenges—treatment resistance. ENV-105 is an antibody specifically designed to target CD105, a protein identified as a key driver of resistance to various cancer therapies. When standard treatments are administered, elevation of CD105 often occurs, leading to resistance and disease relapse. By targeting this mechanism, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard cancer therapies across multiple cancer types. The current Phase 2 trial for prostate cancer and an additional Phase 1 trial for lung cancer represent significant steps toward addressing substantial unmet medical needs in oncology.
This news was distributed through BioMedWire, a specialized communications platform that is part of the Dynamic Brand Portfolio managed by IBN. BioMedWire focuses on delivering the latest developments in biotechnology, biomedical sciences, and life sciences sectors to investors, journalists, and the general public. The platform provides comprehensive distribution services including wire solutions through InvestorWire, article syndication to over 5,000 outlets, enhanced press release optimization, and social media distribution to millions of followers. For those interested in following Kairos Pharma's progress, the company maintains an active newsroom where investors can access the latest updates and developments.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma's Prostate Cancer Therapy Shows 86% Clinical Benefit
